Neo Ivy Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Neo Ivy Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$463K	Buy	+6,439	New	+$367K	0.12%	208
2022 Q2	–	Sell	-272	Closed	-$22K	–	545
2022 Q1	$22K	Buy	272 +229	+533%	+$33.9K	0.02%	424
2021 Q4	$9K	Sell	43 -25	-37%	-$5.42K	0.01%	389
2021 Q3	$24K	Buy	+68	New	+$16.4K	0.03%	382
2021 Q1	–	Sell	-309	Closed	-$79K	–	584
2020 Q4	$79K	Buy	+309	New	+$79.8K	0.09%	272
2020 Q3	–	Sell	-68	Closed	-$24K	–	565
2020 Q2	$24K	Sell	68 -89	-57%	-$27.8K	0.03%	382
2020 Q1	$42K	Buy	+157	New	+$48.6K	0.07%	330
2019 Q1	–	Sell	-1,274	Closed	-$628K	–	369
2018 Q4	$628K	Buy	+1,274	New	+$769K	0.49%	77

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Neo Ivy Capital Management's NKTR Position: Q1 2026 in Review

Neo Ivy Capital Management opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 6,439 shares worth $463K. The stake represents 0.12% of the portfolio and ranks #208 among its holdings. This is a return to the name: Neo Ivy Capital Management previously reported a position in NKTR as recently as Q1 2022.

Neo Ivy Capital Management first reported a position in NKTR in Q4 2018 and has held it in 8 quarters since. The position peaked at $628K in Q4 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Neo Ivy Capital Management held 6,439 shares of Nektar Therapeutics worth $463K as of Q1 2026.
Nektar Therapeutics was a new Neo Ivy Capital Management position in Q1 2026.
Nektar Therapeutics made up 0.12% of Neo Ivy Capital Management's portfolio in Q1 2026, its #208 holding.
Neo Ivy Capital Management first reported a position in Nektar Therapeutics in Q4 2018 and has held it in 8 quarters since.
Neo Ivy Capital Management's Nektar Therapeutics position peaked at $628K in Q4 2018.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.